Faculty: Nicole R. LeBoeuf, MD
Release Date: 05/18/2015
Eleven states have passed laws that prohibit children from indoor tanning. It will take the coordinated effort of many groups to make this unnecessary and dangerous exposure a thing of the past.
On May 29th of 2014, the FDA issued a press release announcing their final decision to reclassify tanning beds. DNA HPAC and many other skin cancer prevention advocates from various organizations, participated in this important call.
2014 has been an exciting year for dermatology nursing. We are thrilled to report that efforts to reduce skin cancer risk for children are progressing.
The DNA's Health Policy and Advocacy Committee has partnered with Drinker Biddle & Reath LLP to assemble documents that you can use as a tool to have your voice heard by your local legislation and Washington, DC.
Biosimilar substitution is an evolving issue that will affect dermatology. Why is this an issue?
The US Food and Drug Administration (FDA) recently issued a proposed order that, if finalized, would significantly strengthen tanning bed regulations.
The DNA Health Policy & Advocacy Committee (HPAC) has been very active so far in 2013 and progress is being made. We are strengthening our collaborations and our expertise is increasingly sought by other advocacy groups because we have...
A press conference was held Monday May 6th to publicly introduce a new proposed FDA order “to increase consumer awareness of tanning bed risks”.
This bill prohibits tanning facilities and operators from allowing individuals who have not attained 18 years of age to use tanning devices.